Too Good to Be True? The Promises and Risks of Compounded Peptides - Frankly Speaking Ep 484

Too Good to Be True? The Promises and Risks of Compounded Peptides - Frankly Speaking Ep 484

May 11, 2026 · 10 min

About this episode

The episode discusses the promises and risks associated with compounded injectable peptides and how to counsel patients on their use.

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-484 Overview: Muscle growth, tissue repair, sexual function—compounded injectable peptides are marketed online for an expanding list of uses, and they’re showing up in your patients’ medicine cabinets. Join us as we explore this growing trend, evaluate the evidence behind the claims, and discuss how to counsel patients on potential safety risks. Episode resource links: Expert Opin Drug Saf. 2026 Mar;25(3):581-588. doi: 10.1080/14740338.2025.2499670HSS J. 2025 Jul 31;21(4):15563316251355551. doi: 10.1177/15563316251355551JAMA 2017;318;(20):2004-2010. doi:10.1001/jama.2017.17069 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

People in this episode

Guest: Robert A. Baldor MD, FAAFP

Topics covered

Keywords

Mentioned in this episode

Organizations: Pri-Med

Books & works: Expert Opin Drug Saf, HSS J, JAMA

More episodes of Pri-Med Podcasts

Explore listener stats, chart rankings, contacts and more on the Pri-Med Podcasts podcast page.